ZONAMPANEL

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H9N5O6.H2O
Molecular Weight	349.2557
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O.OC(=O)CN1C(=O)C(=O)NC2=CC(=C(C=C12)N3C=CN=C3)[N+]([O-])=O

InChI

InChIKey=OBHWTRBRRFQGRJ-UHFFFAOYSA-N

InChI=1S/C13H9N5O6.H2O/c19-11(20)5-17-8-4-9(16-2-1-14-6-16)10(18(23)24)3-7(8)15-12(21)13(17)22;/h1-4,6H,5H2,(H,15,21)(H,19,20);1H2

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C13H9N5O6
Molecular Weight	331.2405
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://clinicaltrials.gov/ct2/show/NCT00044057 | https://clinicaltrials.gov/ct2/show/NCT00044070 | Farooqui Akhlaq A., Neurochemical Aspects of Neurotraumatic and Neurodegenerative Diseases, p. 73, retrieved from:https://books.google.ru/books?id=q_G5aon0WbAC&pg=PA73&redir_esc=y#v=onepage&q&f=false

Zonampanel (also known as YM872) was developed as selective, potent and highly water-soluble competitive alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor antagonist. Zonampanel possesses the neuroprotective effect against focal cerebral ischemia and participated in phase II clinical trials in acute stroke patients. However, because of the severe effects, including hallucinations, agitation, and catatonia the further studied were terminated.

Originator

Approval Year

PubMed

Title	Date	PubMed
Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model.	2003 Apr 25	12706461
Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters.	2004 Oct	15377641
Other neuroprotective therapies on trial in acute stroke.	2006	16651823
Effect of YM872, a selective and highly water-soluble AMPA receptor antagonist, in the rat kindling and rekindling model of epilepsy.	2006 Feb 15	16403498
Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats.	2008 Aug	18443035
Characterization of renal tubular apical efflux of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in humans.	2008 Sep	18609448
What lies behind serum urate concentration? Insights from genetic and genomic studies.	2009 Dec 29	20090896

Sample Use Guides

In Vivo Use Guide

YM872 (ZONAMPANEL) or placebo will be given as a continuous intravenous (iv) infusion for 24 hours

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:48:44 GMT 2023` Edited by `admin` on `Fri Dec 15 15:48:44 GMT 2023`
Record UNII	11G3FV7PG7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZONAMPANEL

Official Name

English

3,4-Dihydro-7-imidazol-1-yl-6-nitro-2,3-dioxo-1(2H)-quinoxalineacetic acid, monohydrate

Common Name

English

YM872

Code

English

1(2H)-QUINOXALINEACETIC ACID,3,4-DIHYDRO-7-(1H-IMIDAZOL-1-YL)-6-NITRO-2,3-DIOXO-, MONOHYDRATE

Common Name

English

YM 872

Common Name

English

ZONAMPANEL MONOHYDRATE

Common Name

English

YM-872

Code

English

ZONAMPANEL [USAN]

Common Name

English

1(2H)-QUINOXALINEACETIC ACID, 3,4-DIHYDRO-7-(1H-IMIDAZOL-1-YL)-6-NITRO-2,3-DIOXO-, HYDRATE (1:1)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C47795